Loading
A phase 1/2 trial of RO7771950, Pertuzumab in her2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05593094 by Hoffmann-La Roche, with 210 participants planned, started 2020-09-03 and due to reach its primary completion in 2027-08-31. Interventions recorded: ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c. Conditions listed: Advanced Solid Tumors, HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares RO7771950, Roche / Genentech, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.
Shares Pertuzumab, HER2-positive breast cancer.